Price (delayed)
$39.825
Market cap
$1.9B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.35
Enterprise value
$1.98B
Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Mirum's lead product candidate, maralixibat,
There are no recent dividends present for MIRM.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.